Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 2ClinicalTrials.gov

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

INTERVENTIONALInicio: 18 de mar de 2025ID: NCT07032662

ReclutandoFase 3ClinicalTrials.gov

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

INTERVENTIONALInicio: 25 de mar de 2025ID: NCT06878261

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy.

INTERVENTIONALInicio: 29 de jun de 2024ID: NCT06015737

ReclutandoFase 3ClinicalTrials.gov

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine

INTERVENTIONALInicio: 30 de jun de 2021ID: NCT04965675

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

INTERVENTIONALInicio: 21 de may de 2024ID: NCT06133972

ReclutandoFase 3ClinicalTrials.gov

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

INTERVENTIONALInicio: 28 de jul de 2025ID: NCT06858319

ReclutandoClinicalTrials.gov

Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY)

OBSERVATIONALInicio: 18 de dic de 2018ID: NCT03797495

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

INTERVENTIONALInicio: 12 de dic de 2025ID: NCT07221474

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

INTERVENTIONALInicio: 25 de jun de 2025ID: NCT07037459

ReclutandoFase 1ClinicalTrials.gov

Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers

INTERVENTIONALInicio: 23 de feb de 2024ID: NCT06312423

ReclutandoClinicalTrials.gov

Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin

INTERVENTIONALInicio: 3 de nov de 2022ID: NCT05575882

ReclutandoFase 3ClinicalTrials.gov

Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)

INTERVENTIONALInicio: 17 de ene de 2024ID: NCT06008197

ReclutandoClinicalTrials.gov

Annual Prevalence of Airway Closure During the Full Support Phase of Invasive Mechanical Ventilation in Adults in an Intensive Care Unit

OBSERVATIONALInicio: 1 de sept de 2025ID: NCT07368491

ReclutandoFase 2ClinicalTrials.gov

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

INTERVENTIONALInicio: 2 de jul de 2025ID: NCT06981078

ReclutandoFase 2ClinicalTrials.gov

A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care

INTERVENTIONALInicio: 21 de feb de 2025ID: NCT06797518

ReclutandoClinicalTrials.gov

Gaucher Disease Registry Protocol

OBSERVATIONALInicio: 1 de abr de 1991ID: NCT00358943

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

INTERVENTIONALInicio: 16 de mar de 2025ID: NCT06841354

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

INTERVENTIONALInicio: 14 de jul de 2025ID: NCT07015983

ReclutandoFase 3ClinicalTrials.gov

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

INTERVENTIONALInicio: 11 de dic de 2023ID: NCT06065748

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

INTERVENTIONALInicio: 5 de mar de 2026ID: NCT07284849